Search Results - "Amato, Carol M"

Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma by Hintzsche, Jennifer D, Gorden, Nicholas T, Amato, Carol M, Kim, Jihye, Wuensch, Kelsey E, Robinson, Steven E, Applegate, Allison J, Couts, Kasey L, Medina, Theresa M, Wells, Keith R, Wisell, Joshua A, McCarter, Martin D, Box, Neil F, Shellman, Yiqun G, Gonzalez, Rene C, Lewis, Karl D, Tentler, John J, Tan, Aik Choon, Robinson, William A

“…Mucosal melanomas are a rare subtype of melanoma, arising in mucosal tissues, which have a very poor prognosis due to the lack of effective targeted therapies…”
Get full text

Long term storage of dry versus frozen RNA for next generation molecular studies by Seelenfreund, Eric, Robinson, William A, Amato, Carol M, Tan, Aik-Choon, Kim, Jihye, Robinson, Steven E

“…The standard method for the storage and preservation of RNA has been at ultra-low temperatures. However, reliance on liquid nitrogen and freezers for storage…”
Get full text

MicroRNA-137 Targets Microphthalmia-Associated Transcription Factor in Melanoma Cell Lines by BEMIS, Lynne T, CHEN, Robert, AMATO, Carol M, CLASSEN, Elizabeth H, ROBINSON, Steven E, COFFEY, David G, ERICKSON, Paul F, SHELLMAN, Yiqun G, ROBINSON, William A

“…Micropthalmia-associated transcription factor (MITF) is the master regulator of melanocyte development, survival, and function. Frequent alteration in the…”
Get full text

Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma by Chen, Robert W., Bemis, Lynne T., Amato, Carol M., Myint, Han, Tran, Hung, Birks, Diane K., Eckhardt, S. Gail, Robinson, William A.

“…Cyclin D1 (CCND1) is a well-known regulator of cell-cycle progression. It is overexpressed in several types of cancer including breast, lung, squamous,…”
Get full text

Clinical and molecular features of subungual melanomas are site-specific and distinct from acral melanomas by Holman, Blair N., Van Gulick, Robert J., Amato, Carol M., MacBeth, Morgan L., Davies, Kurtis D., Aisner, Dara L., Robinson, William A., Couts, Kasey L.

“…Subungual melanomas (SUM) arise beneath the nails of the hands and feet, and account for 0.7–3.5% of all malignant melanomas. Most studies include SUM in the…”
Get full text

A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine by Dart, Chiara R., Mukherjee, Nabanita, Amato, Carol M., Goulding, Anabel, MacBeth, Morgan, Van Gulick, Robert, Couts, Kasey L., Lambert, James R., Norris, David A., Robinson, William A., Shellman, Yiqun G.

“…Although treatment options for melanoma patients have expanded in recent years with the approval of immunotherapy and targeted therapy, there is still an unmet…”
Get full text

IMPACT web portal: oncology database integrating molecular profiles with actionable therapeutics by Hintzsche, Jennifer D, Yoo, Minjae, Kim, Jihye, Amato, Carol M, Robinson, William A, Tan, Aik Choon

“…With the advancement of next generation sequencing technology, researchers are now able to identify important variants and structural changes in DNA and RNA in…”
Get full text

Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma by Khushalani, Nikhil I, Vassallo, Melinda, Goldberg, Judith D, Eroglu, Zeynep, Kim, Younchul, Cao, Biwei, Ferguson, Robert, Monson, Kelsey R, Kirchhoff, Tomas, Amato, Carol M, Burke, Paulo, Strange, Ann, Monk, Emily, Gibney, Geoffrey Thomas, Kudchadkar, Ragini, Markowitz, Joseph, Brohl, Andrew S, Pavlick, Anna, Richards, Alison, Woods, David M, Weber, Jeffrey

“…BackgroundAdjuvant therapy for high-risk resected melanoma with programmed cell-death 1 blockade results in a median relapse-free survival (RFS) of 5 years…”
Get full text

Circulating CD8+ mucosal‐associated invariant T cells correlate with improved treatment responses and overall survival in anti‐PD‐1‐treated melanoma patients by Vorwald, Victoria M, Davis, Dana M, Van Gulick, Robert J, Torphy, Robert J, Borgers, Jessica SW, Klarquist, Jared, Couts, Kasey L, Amato, Carol M, Cogswell, Dasha T, Fujita, Mayumi, Castleman, Moriah J, Davis, Timothy, Lozupone, Catherine, Medina, Theresa M, Robinson, William A, Gapin, Laurent, McCarter, Martin D, Tobin, Richard P

“…Objectives While much of the research concerning factors associated with responses to immune checkpoint inhibitors (ICIs) has focussed on the contributions of…”
Get full text

A Population of Tumor-Infiltrating CD4+ T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance by Mitra, Ankita, Thompson, Brian, Strange, Ann, Amato, Carol M, Vassallo, Melinda, Dolgalev, Igor, Hester-McCullough, Jonathan, Muramatsu, Tomoaki, Kimono, Diana, Puranik, Amrutesh S, Weber, Jeffrey S, Woods, David

“…We previously showed that elevated frequencies of peripheral blood CD3+CD4+CD127-GARP-CD38+CD39+ T cells were associated with checkpoint immunotherapy…”
Get full text

Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity by Newell, Felicity, Wilmott, James S., Johansson, Peter A., Nones, Katia, Addala, Venkateswar, Mukhopadhyay, Pamela, Broit, Natasa, Amato, Carol M., Van Gulick, Robert, Kazakoff, Stephen H., Patch, Ann-Marie, Koufariotis, Lambros T., Lakis, Vanessa, Leonard, Conrad, Wood, Scott, Holmes, Oliver, Xu, Qinying, Lewis, Karl, Medina, Theresa, Gonzalez, Rene, Saw, Robyn P. M., Spillane, Andrew J., Stretch, Jonathan R., Rawson, Robert V., Ferguson, Peter M., Dodds, Tristan J., Thompson, John F., Long, Georgina V., Levesque, Mitchell P., Robinson, William A., Pearson, John V., Mann, Graham J., Scolyer, Richard A., Waddell, Nicola, Hayward, Nicholas K.

“…To increase understanding of the genomic landscape of acral melanoma, a rare form of melanoma occurring on palms, soles or nail beds, whole genome sequencing…”
Get full text

CD4 Phenotypes Are Associated with Reduced Expansion of Tumor-Infiltrating Lymphocytes in Melanoma Patients Treated with Adoptive Cell Therapy by Thompson, Brian, Strange, Ann, Amato, Carol M, Hester-McCullough, Jonathan, Sarnaik, Amod A, Weber, Jeffrey S, Woods, David M

“…Tumor-infiltrating lymphocyte (TIL) adoptive cell therapy is effective in treating malignant melanoma, but its success relies on the adequate ex vivo expansion…”
Get full text

Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma by Nassar, Kelsey W, Hintzsche, Jennifer D, Bagby, Stacey M, Espinoza, Veronica, Langouët-Astrié, Christophe, Amato, Carol M, Chimed, Tugs-Saikhan, Fujita, Mayumi, Robinson, William, Tan, Aik Choon, Schweppe, Rebecca E

“…There is a clear need to identify targetable drivers of resistance and potential biomarkers for salvage therapy for patients with melanoma refractory to the…”
Get full text

MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells by Mukherjee, Nabanita, Skees, Jenette, Todd, Kaleb J., West, Drake A., Lambert, Karoline A., Robinson, William A., Amato, Carol M., Couts, Kasey L., Van Gulick, Robert, MacBeth, Morgan, Nassar, Kelsey, Tan, Aik-Choon, Zhai, Zili, Fujita, Mayumi, Bagby, Stacey M., Dart, Chiara R., Lambert, James R., Norris, David A., Shellman, Yiqun G.

“…Current treatment for patients with metastatic melanoma include molecular-targeted therapies and immune checkpoint inhibitors. However, a subset of melanomas…”
Get full text

Expression Differences in BCL2 Family Members between Uveal and Cutaneous Melanomas Account for Varying Sensitivity to BH3 Mimetics by Mukherjee, Nabanita, Dart, Chiara R., Amato, Carol M., Honig-Frand, Adam, Lambert, James R., Lambert, Karoline A., Robinson, William A., Tobin, Richard P., McCarter, Martin D., Couts, Kasey L., Fujita, Mayumi, Norris, David A., Shellman, Yiqun G.

“…Uveal melanoma (UM) is a subtype of melanoma. Although they share a melanocytic origin with cutaneous melanoma (CM), patients with UM have few treatment…”
Get full text

BH3 mimetics induce apoptosis independent of DRP-1 in melanoma by Mukherjee, Nabanita, Strosnider, Andrew, Vagher, Bay, Lambert, Karoline A., Slaven, Sarah, Robinson, William A., Amato, Carol M., Couts, Kasey L., Bemis, Judson G. T., Turner, Jacqueline A., Norris, David A., Shellman, Yiqun G.

“…Despite the recent advancement in treating melanoma, options are still limited for patients without BRAF mutations or in relapse from current treatments. BH3…”
Get full text

Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy by Amato, Carol M, Hintzsche, Jennifer D, Wells, Keith, Applegate, Allison, Gorden, Nicholas T, Vorwald, Victoria M, Tobin, Richard P, Nassar, Kelsey, Shellman, Yiqun G, Kim, Jihye, Medina, Theresa M, Rioth, Matthew, Lewis, Karl D, McCarter, Martin D, Gonzalez, Rene, Tan, Aik-Choon, Robinson, William A

“…Immunotherapy, such as anti-PD1, has improved the survival of patients with metastatic melanoma. However, predicting which patients will respond to…”
Get full text

Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma by Mukherjee, Nabanita, Amato, Carol M, Skees, Jenette, Todd, Kaleb J, Lambert, Karoline A, Robinson, William A, Van Gulick, Robert, Weight, Ryan M, Dart, Chiara R, Tobin, Richard P, McCarter, Martin D, Fujita, Mayumi, Norris, David A, Shellman, Yiqun G

“…There is an urgent need to develop treatments for patients with melanoma who are refractory to or ineligible for immune checkpoint blockade, including patients…”
Get full text

DNA-PK inhibition enhances neoantigen diversity and increases T cell responses to immunoresistant tumors by Nielsen, Allison Joy, Albert, Gabriella Kyra, Sanchez, Amelia, Chen, Jiangli, Liu, Jing, Davalos, Andres Sebastian, Geng, Degui, Bradeen, Xander G, Hintzsche, Jennifer D, Robinson, William, McCarter, Martin, Amato, Carol M, Tobin, Richard, Couts, Kasey L, Wilky, Breelyn Ann, Davila, Eduardo

“…Effective antitumor T cell activity relies on the expression and MHC presentation of tumor neoantigens. Tumor cells can evade T cell detection by silencing the…”
Get full text

Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments by Mukherjee, Nabanita, Almeida, Adam, Partyka, Katie A, Lu, Yan, Schwan, Josianna V, Lambert, Karoline, Rogers, Madison, Robinson, William A, Robinson, Steven E, Applegate, Allison J, Amato, Carol M, Luo, Yuchun, Fujita, Mayumi, Norris, David A, Shellman, Yiqun G

“…Major limitations of current melanoma treatments are for instances of relapse and the lack of therapeutic options for BRAF wild-type patients who do not…”
Get full text